STOCK TITAN

CONMED Corporation - CNMD STOCK NEWS

Welcome to our dedicated page for CONMED Corporation news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on CONMED Corporation stock.

CONMED Corporation (symbol: CNMD) is a global leader in medical technology, specializing in the development and sale of innovative surgical and patient monitoring products. Headquartered in Utica, New York, CONMED employs approximately 3,500 individuals who are dedicated to improving healthcare quality through high-quality product design, production, and marketing.

The company's core business encompasses a diverse range of specialties, including orthopaedics, general surgery, gynecology, gastroenterology, pulmonology, and anesthesiology. These products are known for their technological advancements, enabling physicians to deliver superior care and achieve enhanced clinical outcomes for their patients.

CONMED operates through two primary reporting units: Orthopedic Surgery and General Surgery. Geographically, the company is U.S.-centric, with the majority of its revenue generated domestically. The EMEA region contributes the second-largest revenue share, followed by APAC and the non-U.S. Americas.

The company's recent achievements include advancements in their surgical products and technology, which continue to set industry standards. Current projects are focused on enhancing product efficiency and expanding their global reach through strategic partnerships and innovations.

CONMED's mission centers around improving healthcare quality. Each employee is committed to customer satisfaction and enhanced patient outcomes, reflecting the company's core values. They strive to exhibit thoughtful leadership, provide meaningful opportunities for employees, and act as a responsible corporate citizen in the communities where they operate.

Recent news highlights include ongoing developments in their product lines and strategic initiatives to bolster market presence. With a strong financial foundation and continuous innovation, CONMED remains a pivotal player in the medical technology sector.

Rhea-AI Summary

CONMED (NYSE: CNMD) is set to release its financial results for the second quarter of 2024 on July 31, 2024, after the market close. A conference call to discuss these results will be hosted by the company's management at 4:30 p.m. ET on the same day. Investors can participate in the conference call by pre-registering to obtain the dial-in number and passcode. The call will also be webcast live on the 'Investors' section of CONMED's website, with a replay available approximately one hour after the call ends.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
-
Rhea-AI Summary

CONMED (NYSE: CNMD) announced that Curt R. Hartman, Chair of the Board, President, and CEO, along with Todd W. Garner, Executive VP and CFO, will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for 8:00 a.m. ET on June 6, 2024.

A live webcast will be accessible via the company's website and will be available for replay following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
conferences
-
Rhea-AI Summary

CONMED (NYSE: CNMD) has announced a quarterly cash dividend of $0.20 per share. The announcement was made on May 22, 2024, and the dividend will be payable on July 5, 2024. Shareholders of record as of June 14, 2024, will be eligible to receive this dividend. This decision reflects the company's ongoing commitment to returning value to its shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
dividends
Rhea-AI Summary

CONMED (NYSE: CNMD) will be presenting at the BofA Securities Healthcare Conference with top executives discussing the company's future on May 14, 2024. The event will be live-streamed on the company's website for investors to access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
conferences
-
Rhea-AI Summary
CONMED promoted Patrick Beyer to Chief Operating Officer, expanding his responsibilities to lead commercial businesses, operations, distribution, regulatory affairs, and customer excellence. Mr. Beyer's promotion reflects his track record of driving above-market growth and expanding the company's presence in key markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.58%
Tags
none
-
Rhea-AI Summary
CONMED reported strong financial results for the first quarter of 2024, with sales reaching $312.3 million, a 5.7% increase year-over-year. Domestic revenue saw a 7.2% growth, while international revenue increased by 3.8%. Diluted net earnings per share were $0.63 (GAAP) compared to $0.06 in Q1 2023, with adjusted diluted net earnings per share at $0.79, a 19.7% increase. The company expects reported revenue for the full year to be between $1.330 billion and $1.355 billion, with adjusted diluted net earnings per share projected in the range of $4.25 to $4.35.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.58%
Tags
Rhea-AI Summary
CONMED (CNMD) will release its first-quarter 2024 financial results on April 24, 2024, followed by a conference call to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
-
Rhea-AI Summary
CONMED Corporation (CNMD) declares a quarterly cash dividend of $0.20 per share, payable on April 5, 2024, to shareholders of record as of March 15, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
dividends
-
Rhea-AI Summary
CONMED Corporation (CNMD) reported a 30.4% increase in sales for the fourth quarter of 2023 compared to the previous year, with domestic revenue up by 33.3%. International revenue also saw a significant increase. The company's full-year 2023 sales increased by 19.1% year over year, with both domestic and international revenues showing strong growth. Adjusted diluted net earnings per share for the fourth quarter of 2023 increased by 152.4% compared to the same period in 2022. The company expects continued growth in 2024, with a projected year-over-year revenue increase of 8% to 10% and adjusted diluted net earnings per share growth of 25% to 28%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.38%
Tags
Rhea-AI Summary
CONMED Corporation (CNMD) to report Q4 2023 financial results on January 31, 2024. Conference call scheduled for 4:30 p.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags

FAQ

What is the current stock price of CONMED Corporation (CNMD)?

The current stock price of CONMED Corporation (CNMD) is $68.63 as of December 20, 2024.

What is the market cap of CONMED Corporation (CNMD)?

The market cap of CONMED Corporation (CNMD) is approximately 2.2B.

What does CONMED Corporation specialize in?

CONMED Corporation specializes in the development and sale of surgical and patient monitoring products across various medical specialties.

Where is CONMED Corporation headquartered?

CONMED Corporation is headquartered in Utica, New York.

How many employees does CONMED Corporation have?

CONMED Corporation employs approximately 3,500 individuals.

What are the main product specialties of CONMED Corporation?

The main product specialties include orthopaedics, general surgery, gynecology, gastroenterology, pulmonology, and anesthesiology.

What are the primary reporting units of CONMED Corporation?

The primary reporting units are Orthopedic Surgery and General Surgery.

In which regions does CONMED Corporation generate most of its revenue?

CONMED Corporation generates most of its revenue in the U.S., followed by the EMEA region, APAC, and the non-U.S. Americas.

What is the mission of CONMED Corporation?

CONMED's mission is to improve healthcare quality by designing, producing, and marketing innovative, high-quality products.

How does CONMED Corporation ensure customer and patient satisfaction?

CONMED focuses on thoughtful leadership, employee opportunities, and responsible community engagement to ensure customer and patient satisfaction.

What recent achievements has CONMED Corporation made?

Recent achievements include advancements in surgical products and technology, enhancing product efficiency and global reach through strategic partnerships.

What is CONMED Corporation's approach to innovation?

CONMED emphasizes continuous innovation by setting industry standards and focusing on product improvements that enhance clinical outcomes.

CONMED Corporation

NYSE:CNMD

CNMD Rankings

CNMD Stock Data

2.17B
30.70M
0.58%
114.64%
7.66%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
LARGO